Pranava Kumar Chaudhary, TNN :
of Patna has contributed as one of the Principal Investigators in the clinical
research and development of new insulin called Insulin Degludec. This molecule
has been developed by Danish pharmaceutical company Novo Nordisk.
Dr Kumar returned from London after presenting his analysis of
the research data at the Insulin Degludec result meeting held in London
This new insulin is far better than existing insulins available
in the market both in terms of efficacy and safety. It is an ultra long acting
drug with a half life of 25 hours. "This makes it eminently suitable for once
daily administration to keep the blood sugar control for 24 hours a day", Dr
Ajay told TOI.
"Another advantage is significant
reduction in the incidence ofhypoglycemia(low
blood sugar), which is a big problem with existing insulins. Insulin Degludec
reduces both total and nocturnal hypoglycemia. Nocturnal hypoglycemia can be
particularly dangerous as the subject might not be aware of its occurrence and
may not take corrective steps to treat"., he claimed .
Unlike currently available insulins,
Degludec does not cause significant weight gain. This is considered a big
advantage as any weight gain in a diabetic subject might increase the risk ofheartdisease.
Degludec can be injected at any time of the day depending upon
what might be the largest meal for that particular individual. This flexibility
is going to make it very user friendly and yet achieve the best possible blood
Dr Ajay Kumar presented the analysis regarding one of the most
wonderful properties of Insulin Degludec called reduced glucose variability.
Peaks and nadirs of blood sugar fluctuations are extremely dangerous with
respect to development of heart disease and other complications of diabetes
affecting kidneys, eyes, nerves and other organs of human body.
Insulin Degludec has shown to reduce the glucose variability in
comparison to the existing insulins. This could be helpful in reducing the
diabetic complications, incidence of hypoglycemia and overall mortality from